Michael C Keefer

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. pmc Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review
    Marnie L Elizaga
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS ONE 8:e54407. 2013
  2. pmc A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults
    Michael C Keefer
    University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America
    PLoS ONE 7:e41936. 2012
  3. pmc Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine
    Sandhya Vasan
    Aaron Diamond AIDS Research Center, New York, New York, United States of America
    PLoS ONE 5:e8816. 2010
  4. pmc HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime
    Cindy M P Duke
    Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Vaccine 25:7410-21. 2007
  5. pmc Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial
    Nina D Russell
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 44:203-12. 2007
  6. ncbi request reprint Safety profile of recombinant canarypox HIV vaccines
    Guy de Bruyn
    HIV Vaccines Trials Network Core Operations, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Vaccine 22:704-13. 2004
  7. ncbi request reprint Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160
    Deborah Lee
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Infect Dis 190:903-7. 2004
  8. pmc A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects
    Michael C Keefer
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA michael
    Vaccine 29:1948-58. 2011
  9. pmc Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine
    Sandhya Vasan
    Aaron Diamond AIDS Research Center, New York, New York, United States of America
    PLoS ONE 5:e8617. 2010
  10. pmc 9G4+ Antibodies Isolated from HIV-Infected Patients Neutralize HIV-1 and Have Distinct Autoreactivity Profiles
    Danielle C Alcena
    Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York, United States of America
    PLoS ONE 8:e85098. 2013

Research Grants

  1. HIV VACCINE CLINICAL TRIALS UNIT
    Michael Keefer; Fiscal Year: 2006

Collaborators

Detail Information

Publications17

  1. pmc Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review
    Marnie L Elizaga
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS ONE 8:e54407. 2013
    ..Here, we report cardiac safety surveillance from 6 phase I trials of MVA vaccines...
  2. pmc A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults
    Michael C Keefer
    University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America
    PLoS ONE 7:e41936. 2012
    ..The trial enrolled 56 healthy HIV-uninfected adults...
  3. pmc Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine
    Sandhya Vasan
    Aaron Diamond AIDS Research Center, New York, New York, United States of America
    PLoS ONE 5:e8816. 2010
    ..Sequences were derived from a prevalent circulating HIV-1 recombinant form in Yunnan, China, an area of high HIV incidence. The objective was to evaluate the safety and immunogenicity of ADMVA in human volunteers...
  4. pmc HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime
    Cindy M P Duke
    Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Vaccine 25:7410-21. 2007
    ..This suggests that initial priming can shape immune response quality after a boost. Overall, these findings provide insight into effective vector combinations for HIV-1 vaccine development...
  5. pmc Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial
    Nina D Russell
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 44:203-12. 2007
    ..We conducted a phase 2 trial to determine if a canarypox vaccine candidate (vCP1452) administered with rgp120 subunit protein would "qualify" for a trial to define a correlate of efficacy...
  6. ncbi request reprint Safety profile of recombinant canarypox HIV vaccines
    Guy de Bruyn
    HIV Vaccines Trials Network Core Operations, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Vaccine 22:704-13. 2004
    ..Reactogenicity does not appear to be related to the number or type of inserted genes, and did not vary between different ALVAC constructs...
  7. ncbi request reprint Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160
    Deborah Lee
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Infect Dis 190:903-7. 2004
    ..4, P =.1, and P =.7, respectively). Persons who acquire HIV-1 infection while enrolled in HIV-1 vaccine trials can be successfully followed after infection, to determine whether vaccines alter the course of HIV-1 infection...
  8. pmc A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects
    Michael C Keefer
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA michael
    Vaccine 29:1948-58. 2011
    ..Thus, a heterologous poxvirus vector prime-boost regimen can induce HIV-specific CD8+ T-cell and CD4+ T-cell responses, which may be an important feature of an optimal regimen for preventive HIV vaccination...
  9. pmc Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine
    Sandhya Vasan
    Aaron Diamond AIDS Research Center, New York, New York, United States of America
    PLoS ONE 5:e8617. 2010
    ..Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high HIV-1 incidence. The objective was to evaluate the safety and immunogenicity of ADVAX in human volunteers...
  10. pmc 9G4+ Antibodies Isolated from HIV-Infected Patients Neutralize HIV-1 and Have Distinct Autoreactivity Profiles
    Danielle C Alcena
    Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York, United States of America
    PLoS ONE 8:e85098. 2013
    ..Further studies of 9G4+ B cells may shed light on the regulation of B cell tolerance and interface between the generation of specific autoreactivities and the induction of antiviral immunity in persons living with HIV. ..
  11. pmc Barriers and Facilitators of Online Patient Portals to Personal Health Records Among Persons Living With HIV: Formative Research
    Amneris E Luque
    Department of Medicine, Infectious Disease Division, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States
    JMIR Res Protoc 2:e8. 2013
    ..However, relatively little is known regarding barriers and facilitators for vulnerable groups such as persons living with human immunodeficiency virus (PLWH)...
  12. pmc 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity
    James J Kobie
    Division of Allergy, University of Rochester Medical Center, Rochester, New York, United States of America
    PLoS ONE 7:e35356. 2012
    ..Our results suggest that the development of HIV BNAbs is not merely a consequence of a general breakdown in tolerance, but rather a more intricate expansion of selective autoreactive B cells and antibodies...
  13. pmc Mathematical modeling of ultradeep sequencing data reveals that acute CD8+ T-lymphocyte responses exert strong selective pressure in simian immunodeficiency virus-infected macaques but still fail to clear founder epitope sequences
    Tanzy M T Love
    Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York 14642, USA
    J Virol 84:5802-14. 2010
    ..Our results suggest that a reservoir of SIV infection is preferentially formed by virus with the transmitted epitope...
  14. pmc Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag
    Kathlyn Santos
    Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States
    Vaccine 25:1634-46. 2007
    ..These findings may have implications for the generation of improved HSV-1 amplicon vectors for HIV-1 vaccine delivery...
  15. doi request reprint Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events
    Claudia Schmidt
    International AIDS Vaccine Initiative, New York, NY, USA
    Hum Vaccin Immunother 8:630-8. 2012
    ..Between 2000 and 2007, the International AIDS Vaccine Initiative sponsored 19 Phase 1 or 2A preventive HIV vaccine trials in the US, Europe, Sub-Saharan Africa and India, enrolling 900 healthy HIV-1 uninfected volunteers...
  16. ncbi request reprint Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A
    Kalpana Gupta
    Department of Medicine, University of Washington, Seattle, Washington, USA
    J Acquir Immune Defic Syndr 29:254-61. 2002
    ..This high-titered preparation of ALVAC-HIV vCP205 in combination with gp120 was safe and immunogenic in a diverse group of HIV-1-seronegative volunteers...
  17. doi request reprint Bridging the digital divide in HIV care: a pilot study of an iPod personal health record
    Amneris E Luque
    Department of Medicine, Infectious Disease Division, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    J Int Assoc Provid AIDS Care 12:117-21. 2013
    ..Persons living with HIV (PLWH) need practical tools to self-manage their condition...

Research Grants1

  1. HIV VACCINE CLINICAL TRIALS UNIT
    Michael Keefer; Fiscal Year: 2006
    ..abstract_text> ..